|
Market Closed -
Nasdaq
23:00:00 17/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.000 USD | +2.04% |
|
-1.64% | -16.90% |
| 08-12 | Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 08-12 | Altimmune, Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | |||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- ALT Stock
- Consensus Altimmune, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
